SCHEMBL640590

SCHEMBL640590

COC(=O)NNC(=O)c1cc(Br)cc(Br)c1N

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.44
STAT3 P40763 1/20 0.43
HSD17B10 Q99714 2/20 0.41
GAA P10253 1/20 0.38
PKM P14618 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
TDP1 Q9NUW8 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
AKR1C4 P17516 1/20 0.35
AKR1C3 P42330 1/20 0.35
AKR1C2 P52895 1/20 0.35
AKR1C1 Q04828 1/20 0.35
LMNA P02545 2/20 0.35
MAPT P10636 2/20 0.35
MEN1 O00255 1/20 0.35
EGFR P00533 1/20 0.35
ERBB2 P04626 1/20 0.35
CYP1A2 P05177 1/20 0.35
LCK P06239 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL639245 0.82 AKR1C4 (0.38) ALDH1A1HSD17B10GAAAKR1C4AKR1C3
SCHEMBL11890093 0.81 ALDH1A1 (0.44) ALDH1A1STAT3HSD17B10GAAPKM
SCHEMBL27953419 0.78 CREBBP (0.41) ALDH1A1HSD17B10GAAAKR1C4AKR1C3
SCHEMBL1119372 0.78 KDM4E (0.49) ALDH1A1HSD17B10GAAAKR1C4AKR1C3
SCHEMBL29562450 0.78 KDM4E (0.49) ALDH1A1HSD17B10GAAAKR1C4AKR1C3
SCHEMBL639100 0.78 HDAC3 (0.36) ALDH1A1HSD17B10RAB9AAKR1C4AKR1C3
SCHEMBL10922064 0.77 KAT6A (0.37) ALDH1A1HSD17B10GAASMN1; SMN2TDP1
SCHEMBL29242839 0.76 ALDH1A1 (0.43) ALDH1A1HSD17B10GAATDP1AKR1C4
SCHEMBL3211571 0.75 HSD17B10 (0.39) ALDH1A1HSD17B10PKMAKR1C4AKR1C3
SCHEMBL3214512 0.75 HSD17B10 (0.39) ALDH1A1HSD17B10AKR1C4AKR1C3AKR1C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8785646-B2 Process for producing amide compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-07-22 US disclosed
US-8541613-B2 Process for producing amide compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-09-24 US disclosed
US-8501951-B2 Process for producing amide compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-08-06 US disclosed
US-20130131348-A1 PROCESS FOR PRODUCING AMIDE COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-05-23 US disclosed
US-20130131371-A1 PROCESS FOR PRODUCING AMIDE COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-05-23 US disclosed
US-20130131349-A1 PROCESS FOR PRODUCING AMIDE COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-05-23 US disclosed
US-8394838-B2 Process for producing amide compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-03-12 US disclosed
EP-2143721-B1 HYDRAZIDE COMPOUND AND HARMFUL ARTHROPOD-CONTROLLING AGENT CONTAINING THE SAME SUMITOMO CHEMICAL CO (JP) 2012-08-15 EP disclosed
EP-2143720-B1 METHOD FOR PRODUCING AMIDE COMPOUND SUMITOMO CHEMICAL CO (JP) 2012-05-16 EP disclosed
US-8119811-B2 Method for producing amide compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-02-21 US disclosed
EP-2189455-A1 PROCESS FOR PRODUCTION OF HYDRAZINE COMPOUND, INTERMEDIATE FOR PRODUCTION OF HYDRAZINE COMPOUND, AND PROCESS FOR PRODUCTION OF THE INTERMEDIATE Sumitomo Chemical Company, Limited (JP) 2010-05-26 EP disclosed
US-20100120866-A1 PROCESS FOR PRODUCING AMIDE COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-05-13 US disclosed
US-20100113794-A1 METHOD FOR PRODUCING AMIDE COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-05-06 US disclosed
US-20100048578-A1 HYDRAZIDE COMPOUND AND HARMFUL ARTHROPOD-CONTROLLING AGENT CONTAINING THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-02-25 US disclosed
US-20100048640-A1 HYDRAZIDE COMPOUND AND HARMFUL ARTHROPOD-CONTROLLING AGENT CONTAINING THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-02-25 US disclosed
EP-2145885-A1 HYDRAZIDE COMPOUND AND HARMFUL ARTHROPOD-CONTROLLING AGENT CONTAINING THE SAME Sumitomo Chemical Company, Limited (JP) 2010-01-20 EP disclosed
EP-2143721-A1 HYDRAZIDE COMPOUND AND HARMFUL ARTHROPOD-CONTROLLING AGENT CONTAINING THE SAME Sumitomo Chemical Company, Limited (JP) 2010-01-13 EP disclosed
EP-2142530-A2 PROCESS FOR PRODUCING PESTICIDAL BENZAMIDE COMPOUNDS Sumitomo Chemical Company, Limited (JP) 2010-01-13 EP disclosed
EP-2143720-A1 METHOD FOR PRODUCING AMIDE COMPOUND Sumitomo Chemical Company, Limited (JP) 2010-01-13 EP disclosed
WO-2008126933-A2 PROCESS FOR PRODUCING PESTICIDAL BENZAMIDE COMPOUNDS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048578-A1 HYDRAZIDE COMPOUND AND HARMFUL ARTHROPOD-CONTROLLING AGENT CONTAINING THE SAME CYC1, L3MBTL4, L3MBTL1 ALDH1A1 153/4885STAT3 4825/4885HSD17B10 2517/4885
US-20100120866-A1 PROCESS FOR PRODUCING AMIDE COMPOUND C9, C5, F3 ALDH1A1 1666/4885STAT3 3066/4885HSD17B10 1727/4885
US-20130131349-A1 PROCESS FOR PRODUCING AMIDE COMPOUND C9, F3, C5 ALDH1A1 1852/4885STAT3 3244/4885HSD17B10 1616/4885
US-20130131371-A1 PROCESS FOR PRODUCING AMIDE COMPOUND C9, F3, C5 ALDH1A1 1852/4885STAT3 3244/4885HSD17B10 1616/4885
US-20100048640-A1 HYDRAZIDE COMPOUND AND HARMFUL ARTHROPOD-CONTROLLING AGENT CONTAINING THE SAME CYC1, L3MBTL1, CBR3 ALDH1A1 179/4885STAT3 4827/4885HSD17B10 2530/4885
US-20130131348-A1 PROCESS FOR PRODUCING AMIDE COMPOUND C9, F3, C5 ALDH1A1 1852/4885STAT3 3244/4885HSD17B10 1616/4885
US-20100113794-A1 METHOD FOR PRODUCING AMIDE COMPOUND CBR3, AOX1, AOC2 ALDH1A1 253/4885STAT3 4285/4885HSD17B10 499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.